The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1-RA as the initial pharmacological therapy for T2DM patients with atherosclerotic cardiovascular disease or obesity and SGLT2-i (alone or in combination with metformin) in those with chronic kidney disease, cardiovascular disease or heart failure [7]. This evidence concerns the gene GLP1R and diabetes mellitus.